Drug Sponsors

Mylan notifies Perrigo of HSR filing regarding proposed acquisition

Monday, April 13, 2015 12:20 PM

Mylan, a global generics and specialty pharmaceutical company, has provided Perrigo, an Irish international manufacturer of over-the-counter pharmaceuticals, with notice of its filing of the pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its proposed acquisition of Perrigo, as required by the HSR Act. Mylan proposed to acquire Perrigo for $205 per share in a cash-and-stock transaction on April 6.

More... »


Roche acquires CAPP Medical, strengthens oncology translational research pipeline

Monday, April 13, 2015 12:18 PM

Roche has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and located in Palo Alto, Calif., to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in blood.

More... »


Pfizer launches competitive grants program for cardiovascular disease research

Friday, April 10, 2015 01:21 PM

Pfizer has launched a new competitive grants program to support research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease. This competitive grants program, which is an extension of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Cardiovascular program, is part of Pfizer's ongoing commitment to translate scientific discoveries into innovative medicines for patients with cardiovascular disease.

More... »

Eisai to restructure U.S. operations, cut workforce 25%

Friday, April 10, 2015 01:19 PM

Eisai Inc., a U.S. subsidiary of Eisai Co., a global R&D-based pharmaceutical company headquartered in Japan, plans to restructure its operations in the U.S., including a reduction of its workforce by approximately 25% across various U.S. functions. This realignment supports Eisai's desire to create a more efficient and focused organization.

More... »

Roche becomes majority shareholder in Foundation Medicine

Thursday, April 9, 2015 01:41 PM

Roche has become a majority shareholder of Foundation Medicine, a molecular information company based in Cambridge, Mass. Roche purchased approximately 15.6 million shares of common stock through a tender offer from Foundation Medicine stockholders at a price of $50 per share.

More... »

Mylan proposes to acquire Perrigo for $205 per share

Thursday, April 9, 2015 01:36 PM

Mylan, a global generics and specialty pharmaceutical company, has made a proposal to acquire Perrigo, an Irish international manufacturer of over-the-counter pharmaceuticals, in a cash-and-stock transaction.

More... »

Arvinas, Merck to collaborate

Wednesday, April 8, 2015 12:41 PM

Arvinas, a New Haven, Conn.-based private biotechnology company creating a new class of drugs based on protein degradation, has formed a strategic collaboration with Merck in which Arvinas' novel PROTAC technology will be used to degrade target proteins to create novel therapeutics. The multi-year collaboration will encompass multiple disease targets across several therapeutic areas.

More... »

GSK to establish global vaccines R&D center in the U.S.

Monday, April 6, 2015 11:57 AM

GlaxoSmithKline is establishing a new global center for vaccines R&D in Rockville, Md. The site will become one of three global vaccines R&D centers for GSK, complementing the company’s existing global R&D center in Rixensart, Belgium and in Siena, Italy, a site GSK acquired from Novartis last month.

More... »

Daiichi Sankyo, Asubio Pharmaceuticals to merge

Friday, April 3, 2015 01:41 PM

Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Company, will merge with its U.S.-based sister company, Asubio Pharmaceuticals. As a result, Asubio Pharmaceuticals projects will be integrated into the Daiichi Sankyo global development organization, led by Mahmoud Ghazzi, M.D., Ph.D.

More... »

TPG completes acquisition of Aptalis, renames company Adare Pharmaceuticals

Thursday, April 2, 2015 01:08 PM

Aptalis Pharmaceutical Technologies has announced that its divestiture from Actavis to TPG, a Texas-based global private investment firm, has been completed. The company also announced its new name is Adare Pharmaceuticals, and John Fraher, who was president of Aptalis Pharmaceutical Technologies, has been named CEO. He is joined by key executives from his current management team.

More... »

CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs